

Birkerød, 09 November 2023

**Indkaldelse til Ekstraordinær Generalforsamling i
ViroGates A/S (CVR-NR. 25 73 40 33)**

Notice to convene an Extraordinary General Meeting of ViroGates A/S

Der indkaldes til ekstraordinær generalforsamling i ViroGates A/S, CVR nr. 25 73 40 33 ("Selskabet"), til afholdelse som fysisk generalforsamling på selskabets adresse, Banevænget 13, 3460 Birkerød,

Notice for an extraordinary general meeting of ViroGates A/S, CVR no. 25 73 40 33 (Company"), is hereby given. The meeting will be held as a physical meeting at the company's address at Banevænget 13, DK-3460 Birkerød,

**fredag den 24. november 2023, kl. 10:00,
Friday, 24 November 2023, 10 AM**

med følgende
with the following

**Dagsorden
Agenda**

1. Valg af dirigent
Election of chairman of the meeting
2. Bemyndigelse til bestyrelsen til at forhøje aktiekapitalen med fortegningsret for selskabets eksisterende aktionærer
Authorisation to the board of directors to increase the share capital with pre-emptive subscription rights for the company's existing shareholders

FULDSTÆNDIGE FORSLAG

FULL PROPOSALS

Ad pkt. 1 / Re item 1

Bestyrelsen foreslår, at advokat Nicolai Jung vælges som dirigent for generalforsamlingen.

The board of directors proposes that attorney-at-law Nicolai Jung be elected as the chairman of the general meeting.

Ad pkt. 2 / Re item 2

Bestyrelsen foreslår, at den bemyndiges til at forhøje aktiekapitalen ved udstedelse af nye aktier med indtil nominelt DKK 3.350.507 med fortegningsret for aktionærerne.

Bestyrelsen foreslår, at bemyndigelsen optages som et nyt punkt 2.4. i vedtægterne. Punkt 2.4 skal have følgende ordlyd:

Punkt 2.4.1:

"Bestyrelsen er indtil den 31. december 2023 bemyndiget til, ad én eller flere gange, at forhøje selskabets aktiekapital ved udstedelse af nye aktier med op til nominelt DKK 3.350.507 med fortegningsret for selskabets aktionærer. Kapitalforhøjelser i henhold til denne bemyndigelse kan gennemføres af bestyrelsen ved kontantindskud. Aktierne kan udstedes til markedskurs eller til en af bestyrelsen fastsat favørkurs."

Punkt 2.4.2:

"For aktier udstedt i henhold til punkt 2.4.1 gælder følgende: De nye aktier er omsætningspapirer udstedt i indehaverens navn og noteret på navn i selskabets ejerbog. Aktierne må ikke have nogen begrænsninger med hensyn til deres omsættelighed, og ingen aktionær er forpligtet til at lade aktierne indløse helt eller delvist. Ingen delvis betaling er tilladt. Aktierne skal have samme rettigheder som den eksisterende aktiekapital og må ikke tilhøre en bestemt aktieklasser. Aktierne giver ret til udbytte og andre rettigheder i selskabet fra tidspunktet for kapitalforhøjelsens registrering hos Erhvervsstyrelsen."

The board of directors proposes that it is authorised to increase the share capital through issuance of new shares with up to nominal DKK 3,350,507 with pre-emptive rights for the shareholders.

The board of directors proposes that the authorisation is adopted as a section 2.4. in the articles of association. Section 2.4 shall have the following wording:

Section 2.4.1:

"The board of directors is until 31 December 2023 authorised, at one or more times, to increase the company's share capital through issuance of new shares with up to nominal DKK 3,350,507 with pre-emptive subscription rights for the company's shareholders. Capital increases according to this authorisation can be carried out by the board of directors by way of cash contributions. The shares may be issued at market price or at a discount price as determined by the board of directors."

Section 2.4.2:

“For shares issued pursuant to section 2.4.1 the following shall apply. The new shares shall be negotiable instruments issued in the name of the holder and registered in the name of the holder in the company's register of shareholders. The shares shall not have any restrictions as to their transferability and no shareholder shall be obliged to have the shares redeemed fully or partly. No partial payment is allowed. The shares shall be with the same rights as the existing share capital and shall not belong to a specific share class. The shares shall give rights to dividends and other rights in the company from the time of registration of the capital increase with the Danish Business Authority.”

DK

Ret til at deltage i og stemme på generalforsamlingen tilkommer aktionærer, som er noteret i ejerbogen på registreringsdatoen eller som senest på registreringsdatoen har anmeldt og dokumenteret deres erhvervelse af aktier i Selskabet med henblik på notering i ejerbogen. Registreringsdatoen er **fredag den 17. november 2023**.

En aktionær eller en fuldmægtig kan deltage på generalforsamlingen med en rådgiver.

Adgangskort

Aktionærer, som ønsker at deltage i generalforsamlingen, skal anmode om et adgangskort senest onsdag den 22. november 2023, kl. 11.59.

Anmodning om adgangskort til den ekstraordinære generalforsamling kan ske:

- online via aktionærportalen på selskabets hjemmeside, <https://www.virogates.com/shareholder-portal/>,
- ved at udfylde, underskrive og fremsende tilmeldingsblanketten pr. e-mail til gf@computershare.dk eller med almindelig post til Computershare A/S, Lottenborgvej 26 D, 1., 2800 Kgs. Lyngby, eller ved at anvende tilmeldingsblanketten, som er tilgængelig på selskabets hjemmeside, <https://www.virogates.com/announcements>, under selskabsmeddelelsen vedr. indkaldelsen til generalforsamlingen. Vær opmærksom på postvæsenets leveringstid, hvis tilmeldingsblanketten sendes med almindelig post, eller
- ved at kontakte Computershare A/S, Lottenborgvej 26 D, 1., 2800 Kgs. Lyngby, på telefon 4546 0997 (hverdage fra 9.00 til 15.00).

Adgangskort og oplysninger om, hvordan man deltager i generalforsamlingen, vil blive sendt til den e-mailadresse, der er angivet i aktionærportalen ved tilmeldingen.

Stemmeafgivelse ved fuldmagt og brevstemmer

En aktionær kan udøve sine aktionærrettigheder ved at afgive fuldmagt *eller* brevstemme, men ikke begge dele. Afgivelse af fuldmagt eller brevstemme kan ske elektronisk via aktionærportalen på selskabets hjemmeside, <https://www.virogates.com/shareholder-portal/>. Login kræver et brugernavn og en adgangskode eller MitID. Fuldmagtstemmer og brevstemmer kan også ske ved at bruge de blanketter, der er tilgængelige på selskabets hjemmeside, <https://www.virogates.com/announcements>, under selskabsmeddelelsen vedr. indkaldelsen til generalforsamlingen. Den udfyldte blanket skal sendes med almindelig post til Computershare A/S, Lottenborgvej 26 D, 1., 2800 Kgs. Lyngby, eller pr. e-mail til gf@computershare.dk.

Angivelse af den fuldmægtige skal være indsendt senest onsdag den 22. november 2023, kl. 11.59, og brevstemmer skal være modtaget af selskabet eller Computershare A/S i overensstemmelse med ovenstående senest torsdag den 23. november 2023 kl. 16.00.

Yderligere oplysninger

Frem til og med dagen for generalforsamlingen vil følgende yderligere oplysninger om generalforsamlingen være tilgængelige på Selskabets hjemmeside, www.virogates.com:

- Indkaldelse med dagsorden, fuldstændige forslag og bilag.
- De dokumenter, der skal fremlægges på generalforsamlingen, herunder vedtægter
- Det samlede antal aktier og stemmerettigheder på datoen for indkaldelsen
- Fuldmagts- og brevstemmeblanket

Forslaget under pkt. 2 skal vedtages med mindst to tredjedele af de afgivne stemmer og den på generalforsamlingen repræsenterede aktiekapital. Selskabets eksisterende aktiekapital udgør nominelt DKK 3.350.507 fordelt på 3.350.507 aktier à nominelt DKK 1. Hver aktie à nominelt DKK 1 giver én stemme på generalforsamlingen.

UK

The right to attend and vote at a general meeting may be exercised by shareholders who are registered in the share register on the record date or who have announced and documented their acquisition of shares for the purpose of registration in the share register by the record date. The record date is **Friday 17 November 2023**.

A shareholder or a proxy may attend the extraordinary general meeting together with an adviser.

Admission card

Admission cards for the Annual General Meeting may be requested no later than on Wednesday, 22 November 2023 at 11:59 am:

- online via the shareholder portal on the company's website, <https://www.virogates.com/shareholder-portal/>,
- by completing, signing and submitting the registration form by email to gf@computershare.dk or by ordinary mail to Computershare A/S, Lottenborgvej 26 D, first floor, 2800 Kgs. Lyngby, Denmark, or by using the registration form available on the company's website, <https://www.virogates.com/announcements>, attached to the company announcement regarding the extraordinary general meeting. Please note the delivery time of the postal services if the registration form is sent by ordinary mail; or
- by contacting Computershare A/S, Lottenborgvej 26 D, first floor, 2800 Kgs. Lyngby, Denmark on tel. +45 4546 0997 (weekdays from 9:00 am to 3:00 pm CEST).

Admission cards and details on how to participate in the General Meeting will be sent to the email address specified in the shareholder portal upon registration.

Proxy and postal votes

You will be able to exercise your shareholder rights by issuing a proxy or by submitting a postal vote, but you cannot do both. The granting of proxy and postal voting can take place electronically via the shareholder portal available at <https://www.virogates.com/shareholder-portal/>. Login requires username and password or MitID. Proxy and postal voting can also take place using the forms available on the company's website, <https://www.virogates.com/announcements>, attached to the company announcement regarding the extraordinary general meeting. The completed form must be sent by ordinary mail to Computershare A/S, Lottenborgvej 26 D, first floor, DK-2800 Kgs. Lyngby, Denmark or by email to gf@computershare.dk.

Nomination of proxy must be received by the company or Computershare A/S in accordance with the above no later than Wednesday, 22 November 2023 at 11:59 am and postal votes must be received by the company or Computershare A/S in accordance with the above no later than Thursday 23 November 2023 at 4:00 pm CET.

Additional information

Until and including the day of the annual general meeting, additional information regarding the annual general meeting will be available on the Company's website, www.virogates.com:

- Notice to convene the annual general meeting with agenda, complete proposals and appendices.
- Documents to be presented at the annual general meeting, Articles of Association
- Information about the total number of shares and voting rights on the date of notice to convene
- Proxy and correspondence voting forms

The proposal under item 2 must be adopted by at least two-thirds of the votes cast and the share capital represented at the general meeting. The Company's existing share capital is nominal DKK 3,350,507 divided into 3,350,507 shares of nominal DKK 1. Each share of nominal DKK 1 carries one vote at the general meeting.

For further information please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, France and Benelux, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is a biomarker detected by ViroGates' suPARnostic® products. It is a protein found in the plasma. suPAR is considered a general risk status biomarker indicating inflammation and can indicate disease presence, severity, and progression across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 800 clinical trials and studies shows that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalisation or discharge of acute care patients. The increasing global demands on health systems and tightening healthcare budgets necessitate efficiency improvements and innovative hospital solutions. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length of stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.